Neurology Order Form



Fax Completed Form To: 844-815-2606

	PATIENT INFORMATION				
Patient Name:	Date of Birth:		Referral Date:		
Address:			City/State/Zip:		
Home Phone:	Cell Phone:		Work Phone:		
Secondary Contact:	Height:	Weight:	Male Female		
Patient Diagnosis & ICD-10:					
Allergies:					
PROVIDER INFORMATION					
Physician Name:	Lic.#:		DEA #:		
Practice Name:			NPI#:		
Address:			City/State/Zip:		
Office Contact:	Phone:		Fax:		
Supervisory Physician (if applicable):					
PLEASE ATTACH					
Patient demographics & front/back copy of all insurance cards (prescription & medical) Vaccine status (any vaccination) and documentation of any recent vaccinations					
Recent office visit notes, history & physical, lab & pertinent procedure results HBV lab results within last 12 months (Uplizna only)					
Current medication list & list of prior medications tried and failed (with dates) Date of diagnosis, current FVC%, ALSFRS-R score, and JourneyMate form (Radicava only)					
Line access documentation/verification if applicable Anti-acetylcholine receptor (AChR) antibody positive results (Vyvgart)					
Quantitative serum Immunoglobulin lab results (Uplizna only) Letter of medical necessity if drug dosing or indication is outside of FDA guidelines					
TB lab results within last 12 months (Uplizna only)					
NURSING & LAB ORDERS					
Nurse Orders: Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders.					
Flush Orders: NaCl 0.9% - 5-10mL flush pre and post infusion and as needed Heparin - 10units/mLOR 100units/mL - 3-5mL flush after post-infusion NS flush if indicated to maintain line					
Lab Orders: Lab Date & Frequency:					
PRESCRIPTION ORDERS					
Anaphylaxis Kit: Epinephrine 0.3mg IM as needed Solu-cortef 250mg-500mg IV as needed Solu-Medrol 60mg - 125mg IV as needed					
(Check all that apply) Diphenhydramine mg IV as needed NS Hydration 500 ml IV over 30 minutes as needed Other					
Pre-Medications: Acetaminophenmg P0minutes prior to infusion Solu-Medrolmg IVminutes prior to infusion					
(Check all that apply) Diphenhydramine mg POOR IV minutes prior to infusion Other					
Supply Orders: All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary					
PRODUCT	P	RESCRIPTION INFORMAT	ΓΙΟΝ	REFILLS	
Is this a first dose? Yes No If No, when was last dose given?When is patient due for next dose?					
RADICAVA	Induction: 60mg IV infusion via gravityOR	pump over 1 hour daily for 14 days foll	lowed by 14 day drug-free period	NONE	
	Maintenance: 60mg IV infusion via gravityOR	pump over 1 hour daily for 10 days o	out of 14 day period followed by 14 day drug-free periods		
UPLIZNA	Induction: 300mg IV infusion via gravityOR	pump over approximately 90 minute	es at 0 and 2 weeks and CBC lab testing every months	NONE	
	Maintenance: (starting 6 months from first infusion) 300	mg IV infusion via gravity OR	pump over approximately 90 minutes every 6 months		
	100mg IV infusion via gravity OR pump over	approximately 30 minutes every 12 we	peks		
VYEPTI		approximately 30 minutes every 12 we			
VYVGART			r 4 weeks		
	*Up to max of 1200mg for patient weight of 120kg+ (Total volume is 125ml in NS solution) Administer additional treatment cycles every 50 days OR Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle				
	According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established.				
VYVGART HYTRULO			weakly injections for A weaks		
	1,008mg/11,200 units subcutaneous injection over approximately 30 to 90 seconds in cycles of once weekly injections for 4 weeks Administer additional treatment cycles every 50 days OR Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle				
	According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days				
	from the start of the previous treatment cycle has not been established.				
IG	Refer to Immunoglobulin Form				
SOLIRIS/ULTOMIRIS	Refer to Soliris or Ultomiris Order Form				
OTHER				NONE	
By signing this form and utilizing our services, you are authorizing Amerita to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.					
שי אינו אינו אינו אינו אינו אינו אינו אינ					

Date

Prescriber's Signature Substitution Permitted Print Name



